Oligometastatic pancreatic cancer – prognostic factors for oncosurgical individualized therapy

Czech version

Authors: B. Mohelníková Duchoňová ¹; H. Švébišová ¹; A. Langer ¹; P. Skalický ²; J. Tesaříková ²; M. Gregořík ²; M. Loveček ²
Authors‘ workplace: Onkologická klinika, LF UP a FN Olomouc ¹; I. chirurgická klinika, LF UP a FN Olomouc ²
Published in: Rozhl. Chir., 2024, roč. 103, č. 11, s. 421-428.
Category: Review
doi: https://doi.org/10.48095/ccrvch2024421

Overview

Currently, no international consensus includes surgery as part of the standard of metastatic pancreatic ductal adenocarcinoma care. There is weak evidence to support the general introduction of surgical resection in the metastatic pancreatic ductal adenocarcinoma treatment. However, in the rare cases of oligometastatic spread there is increasing evidence that surgical intervention can lead to favourable outcomes. Individualisation of the care and tailored therapy refers not only to targeted treatment but also to the whole complex cancer care, including the indication for surgery. This review summarizes the current status of combined oncosurgical therapy in the multidisciplinary management of oligometastatic pancreatic cancer, together with our own experience, and discusses future perspectives, particularly regarding prognostic and predictive factors that could better predict this group.

Keywords:

Pancreatic cancer – metastasis – neoadjuvant chemotherapy – metastasectomy

Sources

1. Leonhardt CS, Stamm T, Hank T et al. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus. ESMO Open 2023; 8(6): 102067. doi: 10.1016/j.esmoop.2023.102067.

2. Rim CH, Cho WK, Lee JH et al. Role of local treatment for oligometastasis: a comparability-based meta-analysis. Cancer Res Treat 2022; 54(4): 953–969. doi: 10.4143/crt.2022.329.

3. Joharatnam-Hogan N, Wilson W, Shiu KK et al. Multimodal treatment in metastatic colorectal cancer (mCRC) improves outcomes – the University College London Hospital (UCLH) experience. Cancers (Basel) 2020; 12(12): 3545. doi: 10.3390/cancers12123545.

4. Marshall JL. Managing potentially resectable metastatic colon cancer. Gastrointest Cancer Res 2008; 2(Suppl 4): S23–S26.

5. Cloyd JM, Wiseman JT, Pawlik TM. Surgical management of pancreatic neuroendocrine liver metastases. J Gastrointest Oncol 2020; 11(3): 590–600. doi: 10.21037/jgo.2019.11.02.

6. NCCN. NCCN Guidelines. [online]. Dostupné z: https://www.nccn.org/Guidelines/Guidelines-Detail?Category=1&Id=1455.

7. Conroy T, Pfeiffer P, Vilgrain V et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34(11): 987–1002. doi: 10.1016/j.annonc.2023.08.009.

8. Frigerio I, Regi P, Giardino A et al. Downstaging in stage IV pancreatic cancer: a new population eligible for surgery? Ann Surg Oncol 2017; 24(8): 2397–2403. doi: 10.1245/s10434-017-5885-4.

9. Conroy T, Hammel P, Hebbar M et al. Folfirinox or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018; 379(25): 2395–2406. doi: 10.1056/NEJMoa1809775.

10. Hackert T, Niesen W, Hinz U et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol 2017; 43(2): 358–363. doi: 10.1016/j.ejso.2016.10.023.

11. Horn SR, Stoltzfus KC, Lehrer EJ et al. Epidemiology of liver metastases. Cancer Epidemiol 2020; 67: 101760. doi: 10.1016/j.canep.2020.101760.

12. Loveček M, Skalický P, Urban O et al. Isolated gastric metastases of pancreatic ductal adenocarcinoma following radical resection-impact of endosonography-guided fine needle aspiration tract seeding. Biomedicines 2022; 10(6): 1392. doi: 10.3390/biomedicines10061392.

13. Lovecek M, Skalicky P, Chudacek J et al. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: retrospective study and review of the literature. World J Gastroenterol 2017; 23(35): 6420–6428. doi: 10.3748/wjg.v23.i35.6420.

14. Zanini N, Lombardi R, Masetti M et al. Surgery for isolated liver metastases from pancreatic cancer. Updates Surg 2015; 67(1): 19–25. doi: 10.1007/s13304-015-0283-6.

15. Arnaoutakis GJ, Rangachari D, Laheru DA et al. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg 2011; 15(9): 1611–1617. doi: 10.1007/s11605-011-1605-8.

16. Wright GP, Poruk KE, Zenati MS et al. Primary tumor resection following favorable response to systemic chemotherapy in stage IV pancreatic adenocarcinoma with synchronous metastases: a bi-institutional analysis. J Gastrointest Surg 2016; 20(11): 1830–1835. doi: 10.1007/s11605-016-3256-2.

17. Thomas RM, Truty MJ, Nogueras-Gonzalez GM et al. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg 2012; 16(9): 1696–1704. doi: 10.1007/s11605-012-1912-8.

18. Tachezy M, Gebauer F, Janot M et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery 2016; 160(1): 136–144. doi: 10.1016/j.surg.2016.02.019.

19. Downs-Canner S, Zenati M, Boone BA et al. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas. J Surg Oncol 2015; 112(1): 80–85. doi: 10.1002/jso.23943.

20. Robinson LA, Tanvetyanon T, Springett G et al. Pulmonary metastasectomy for suspected pancreaticobiliary cancer. J Thorac Cardiovasc Surg 2016; 152(1): 75–82. doi: 10.1016/j.jtcvs.2016.02.066.

21. Shi HJ, Jin C, Fu DL. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: diagnosis and assessment of unresectability. World J Gastroenterol 2016; 22(45): 10024–10037. doi: 10.3748/wjg.v22.i45.10024.

22. Yasukawa M, Kawaguchi T, Kawai N et al. Surgical treatment for pulmonary metastasis of pancreatic ductal adenocarcinoma: study of 12 cases. Anticancer Res 2017; 37(10): 5573–5576. doi: 10.21873/anticanres.11990.

23. Tanaka M, Heckler M, Mihaljevic AL et al. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Eur J Surg Oncol 2019; 45(8): 1453–1459. doi: 10.1016/j.ejso.2019.03.039.

24. Okui M, Yamamichi T, Asakawa A et al. Resection for pancreatic cancer lung metastases. Korean J Thorac Cardiovasc Surg 2017; 50(5): 326–328. doi: 10.5090/kjtcs.2017.50.5.326.

25. Yang J, Zhang J, Lui W et al. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection. HPB (Oxford) 2020; 22(1): 91–101. doi: 10.1016/j.hpb.2019.05.015.

26. Groot VP, Blair AB, Gemenetzis G et al. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. HPB (Oxford) 2019; 21(8): 998–1008. doi: 10.1016/j.hpb.2018.12.002.

27. Safi SA, Fluegen G, Rehders A et al. Surgical margin clearance and extended chemotherapy defines survival for synchronous oligometastatic liver lesions of the ductal adenocarcinoma of the pancreas. Int J Clin Oncol 2021; 26(10): 1911–1921. doi: 10.1007/s10147-021-01961-5.

28. Ilmer M, Schiergens TS, Renz BW et al. Oligometastatic pulmonary metastasis in pancreatic cancer patients: safety and outcome of resection. Surg Oncol 2019; 31: 16–21. doi: 10.1016/j.suronc.2019.08.010.

29. Shao Y, Feng J, Hu Z et al. Feasibility of pancreaticoduodenectomy with synchronous liver metastasectomy for oligometastatic pancreatic ductal adenocarcinoma – a case-control study. Ann Med Surg (Lond) 2021; 62: 490–494. doi: 10.1016/j.amsu.2020.11.037.

30. Mashiko T, Nakano A, Masuoka Y et al. Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study. BMC Surg 2021; 21(1): 237. doi: 10.1186/s12893-021-01236-w.

31. Bachellier P, Addeo P, Averous G et al. Resection of pancreatic adenocarcinomas with synchronous liver metastases: a retrospective study of prognostic factors for survival. Surgery 2022; 172(4): 1245–1250. doi: 10.1016/j.surg.2022.03.003.

32. Homma Y, Endo I, Matsuyama R et al. Outcomes of lung metastasis from pancreatic cancer: a nationwide multicenter analysis. J Hepatobiliary Pancreat Sci 2022; 29(5): 552–561. doi: 10.1002/jhbp.1127.

33. Hamad A, Underhill J, Ansari A et al. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: an analysis of the National Cancer Database. Surgery 2022; 171(6): 1464–1470. doi: 10.1016/j.surg.2021.12.029.

34. Nagai M, Wright MJ, Ding D et al. Oncologic resection of pancreatic cancer with isolated liver metastasis: favorable outcomes in select patients. J Hepatobiliary Pancreat Sci 2023; 30(8): 1025–1035. doi: 10.1002/jhbp.1303.

35. Klein F, Puhl G, Guckelberger O et al. The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Gastroenterol Res Pract 2012; 2012: 939350. doi: 10.1155/2012/939350.

36. Ren W, Xourafas D, Ashley SW et al. Temporal assessment of prognostic factors in patients with pancreatic ductal adenocarcinoma undergoing neoadjuvant treatment and resection. J Surg Res 2021; 257: 605–615. doi: 10.1016/j.jss.2020.07.073.

37. Crippa S, Bittoni A, Sebastiani E et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol 2016; 42(10): 1533–1539. doi: 10.1016/j.ejso.2016.06.398.

38. Hua YQ, Wang P, Zhu XY et al. Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: an analysis of safety and efficacy. Pancreatology 2017; 17(6): 967–973. doi: 10.1016/j.pan.2017.08.072.

39. Takeda T, Sasaki T, Okamoto T et al. Outcomes of pancreatic cancer with liver oligometastasis. J Hepatobiliary Pancreat Sci 2023; 30(2): 229–239. doi: 10.1002/jhbp.1184.

40. Tanaka M, Mihaljevic AL, Probst P et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg 2019; 106(12): 1590–1601. doi: 10.1002/bjs.11295.

41. Lee KJ, Yi SW, Chung MJ et al. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J 2013; 54(3): 643–649. doi: 10.3349/ymj.2013.54.3.643.

42. Kim HJ, Lee SY, Kim DS et al. Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy. Korean J Intern Med 2020; 35(1): 171–184. doi: 10.3904/kjim.2018.076.

43. Satoi S, Yamamoto T, Yamaki S et al. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2020; 4(1): 6–13. doi: 10.1002/ags3.12295.

44. Wahl RL, Jacene H, Kasamon Y et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50(Suppl 1): 122S–150S. doi: 10.2967/jnumed.108.057307.

45. Panda A, Garg I, Truty MJ et al. Borderline resectable and locally advanced pancreatic cancer: FDG PET/MRI and CT tumor metrics for assessment of pathologic response to neoadjuvant therapy and prediction of survival. AJR Am J Roentgenol 2021; 217(3): 730–740. doi: 10.2214/ajr.20.24567.

46. Abdelrahman AM, Goenka AH, Alva-Ruiz R et al. FDG-PET predicts neoadjuvant therapy response and survival in borderline resectable/locally advanced pancreatic adenocarcinoma. J Natl Compr Canc Netw 2022; 20(9): 1023.e3–1032.e3. doi: 10.6004/jnccn.2022.7041.

47. Wei M, Shi S, Hua J et al. Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). BMJ Open 2019; 9(12): e033452. doi: 10.1136/bmjopen-2019-033452.

48. Gebauer F, Damanakis AI, Popp F et al. Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC). BMC Cancer 2021; 21(1): 1239. doi: 10.1186/s12885-021-08966-3.

49. Hlavac V, Mohelnikova-Duchonova B, Lovecek M et al. Targeted sequencing of pancreatic adenocarcinomas from patients with metachronous pulmonary metastases. Genes (Basel) 2020; 11(12): 1391. doi: 10.3390/genes11121391.

50. Zhu Y, Zhang H, Chen N et al. Diagnostic value of various liquid biopsy methods for pancreatic cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2020; 99(3): e18581. doi: 10.1097/md.0000000000018581.

51. Lee B, Lipton L, Cohen J et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Ann Oncol 2019; 30(9): 1472–1478. doi: 10.1093/annonc/mdz200.

52. Court CM, Ankeny JS, Sho S et al. Circulating tumor cells predict occult metastatic disease and prognosis in pancreatic cancer. Ann Surg Oncol 2018; 25(4): 1000–1008. doi: 10.1245/s10434-017-6290-8.

53. Uesato Y, Sasahira N, Ozaka M et al. Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis. PLoS One 2020; 15(7): e0235623. doi: 10.1371/journal.pone.0235623.

prof. MUDr. Beatrice Mohelníková Duchoňová, Ph.D.

Onkologická klinika

LF UP a FN Olomouc

Zdravotníků 248/7

779 00 Olomouc

BeatriceMohelnikova.Duchonova@fnol.cz